[Principles of rational tuberculosis chemotherapy].
Experimental and clinical studies showed that there were rapidly and slowly growing, as well as persisting mycobacteria, including variants in L-forms. Combinations of isoniazid, streptomycin and PAS mainly affected rapidly growing variants of mycobacteria, while isoniazid and rifampicin in combination with streptomycin, protionamide or ethambutol had the most pronounced bacteriostatic effect on all mycobacterial variants. Discontinuation of the bacteria isolation was observed by the end of the 4th, 6th and 9th months of the treatment in 73.9, 93 and 96 per cent of the newly recorded patients with cavernous tuberculosis respectively. Closing of the caverns in the same periods was observed in 26.1, 68.4 and 81.4 per cent of the patients. In patients with rapid discontinuation of the bacteria isolation, i. e. within the first 3 months of the treatment a rapid closing of the caverns was also recorded.
D010131:Aminosalicylic Acid / Q000627:therapeutic use; D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D006168:Guinea Pigs; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D051379:Mice; D011515:Prothionamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D010131:Aminosalicylic Acid; D011515:Prothionamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Printsipy ratsional'noĭ khimioterapii tuberkuleza.